ClinicalTrials.Veeva

Menu

Study of a Series of Patients Treated for Retrograde Cricopharyngeal Muscle Dysfunction Syndrome (R-CPD-Syndrome)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Deglutition Disorders

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

R-CPD syndrome (Retrograde Cricopharyngeal Dysfunction syndrome) is an inability to burp.

It is a syndrome whose diagnosis is clinical, and for which there is effective treatment. Recently treated in the United States (first publication in 2019), this syndrome affects many patients in France and is currently unknown.

This study concerns a series of patients treated at the University Hospitals of Strasbourg for a syndrome of retrograde dysfunction of the cricopharyngeus muscle having been treated by injection of botulinum toxin into the cricopharyngeus muscle.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major subject (≥18 years old)
  • Subject treated by injection of botulinum toxin into the cricopharyngeal muscle after having had a diagnosis of R-CPD in consultation between January 1, 2022 and December 31, 2022
  • Subject not opposing the reuse of their data for the purposes of this research.

Exclusion criteria

  • Subject having expressed opposition to participating in the study,
  • Subject under judicial protection
  • Subject under guardianship or curatorship

Trial contacts and locations

1

Loading...

Central trial contact

Christian DEBRY, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems